小剂量阿帕替尼联合FOLFOX方案对晚期结直肠癌的应用效果及相关肿瘤标志物的影响  

The Application Effect of Low-dose Apatinib Combined with FOLFOX Regimen on Advanced Colorectal Cancer and the Influence of Related Tumor Marker

作　　者：韩恒昌 申建宇 崔军召 HAN Hengchang;SHEN Jianyu;CUI Junzhao(Yuzhou People's Hospital,Henan Yuzhou 461670)

机构地区：[1]禹州市人民医院,河南禹州461670

出　　处：《深圳中西医结合杂志》2024年第20期90-93,共4页Shenzhen Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的:探讨小剂量阿帕替尼联合亚叶酸钙+奥沙利铂+5-氟尿嘧啶(FOLFOX)方案治疗晚期结直肠癌的效果及对相关肿瘤标志物水平影响。方法:选取禹州市人民医院2020年3月至2022年3月收治的80例晚期结直肠癌患者作为研究对象,应用抽签法分为观察组与对照组,各组均为40例。对照组患者采取FOLFOX方案化疗,观察组患者采取小剂量阿帕替尼联合FOLFOX方案治疗。比较两组患者的临床疗效,生存期与生存率,不良反应发生率,治疗前后血清相关肿瘤标志物水平变化、生存质量与癌因性疲乏程度。结果:观察组患者疾病控制率、客观缓解率、中位总生存期、中位无进展生存、1年生存率、2年生存率均明显高于对照组(P<0.05);治疗后观察组患者血清环氧化酶-2(COX-2)、癌胚抗原(CEA)、基质金属蛋白酶-2(MMP-2)、糖类抗原199(CA199)水平低于对照组,差异均具有统计学意义(P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05);治疗后观察组患者世界卫生组织生存质量测定量表简表(WHOQOL-BREF)评分高于对照组,癌因性疲乏量表(CRF)评分低于对照组,差异均具有统计学意义(P<0.05)。结论:小剂量阿帕替尼联合FOLFOX方案可改善晚期结直肠癌患者的临床疗效,提升其生存期与远期生存率,降低患者血清肿瘤标志物水平,安全性较高,提高患者生存质量,减轻癌因性疲乏程度。Objective To explore the efficacy of low-dose apatinib combined with calcium folinate+oxaliplatin+5-fluorouracil(FOLFOX)regimen in the treatment of advanced colorectal cancer and the impact of serum related tumor marker levels.Methods A total of 80 patients with advanced colorectal cancer admitted to Yuzhou People's Hospital from March 2020 to March 2022 were selected as the study subjects and divided into an observation group and a control group using the lottery method,with 40 cases in each group.The control group received FOLFOX chemotherapy,while the observation group received low-dose apatinib combined with FOLFOX chemotherapy.The clinical efficacy,survival period and rate,incidence of adverse reactions,changes in serum tumor markers,quality of life and cancer-related fatigue before and after treatment between two groups of patients were compared.Results The disease control rate,objective response rate,median overall survival,median progression-free survival,1-year survival rate and 2-year survival rate in observation group were significantly higher than those in control group,with statistical significance(P<0.05).After treatment,the serum levels of cyclooxygenase-2(COX-2),carcinoembryonic antigen(CEA),matrix metalloproteinase-2(MMP-2)and carbohydrate antigen 199(CA199)in observation group were lower than those in control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After treatment,the WHOQOL-BREF score of the observation group was higher than that of the control group,and the CRF score was lower than that of the control group,with statistical significance(P<0.05).Conclusion The combination of low-dose apatinib and FOLFOX regimen can improve the clinical efficacy of advanced colorectal cancer,enhance its survival and long-term survival rates,and reduce the serum tumor marker levels of patients.It has high safety,improves the quality of life of patients,and reduces the degree of cancer-

关 键 词：结直肠癌 阿帕替尼 FOLFOX方案 肿瘤标志物 

分 类 号：R735.3[医药卫生—肿瘤]